The CBD-terpene regimen significantly increased the percentage of time (11.9 ± 1.9%) and absolute time (51.8 ± 8.9 min/night) spent in SWS and REM sleep without affecting total sleep time.
Successful management of OSA was associated with a significant reduction in systolic blood pressure (SBP) in hypertensive patients. Specifically, CPAP treatment resulted in a greater improvement in SBP z-score percentile compared to surgical treatment. However, no significant impact on body mass index (BMI) was observed in obese patients.
Reduction in Insomnia Severity Index (ISI) scores and improvement in self-reported sleep quality and perception of sleep after CBTi, although objective sleep and cognitive functioning did not show improvement.
CBT-I resulted in a long-term remission rate of 41%, compared to 28% for pharmacotherapy. It also had lower dropout rates and was associated with better short-term outcomes, except for total sleep time.
The primary outcome is treatment efficacy, defined as remission measured by validated self-reported scales at four weeks post-treatment. Secondary outcomes include acceptability and improvements in sleep diary measures.
Exercise training alone led to moderate improvements in insomnia severity, while the combination of CBTi and exercise training resulted in larger reductions in insomnia symptoms, with effect sizes comparable to CBTi alone in other populations.
Patients with OSA who were not treated with CPAP had significantly lower in-hospital mortality and resource utilization compared to those who received CPAP.
The study found that effective CBT-I packages can include cognitive restructuring, sleep restriction, and stimulus control, leading to improved treatment efficacy for chronic insomnia.
Expected positive outcomes include improved sleep quality as measured by the Pittsburgh Sleep Quality Index and reductions in fatigue, depression, and anxiety levels.
Positive outcomes include significant reductions in insomnia severity as measured by the Insomnia Severity Index (ISI), improved patient-reported outcomes related to sleep quality, daytime functioning, and overall health status. The study aims to demonstrate the effectiveness of the PDT in real-world settings, potentially leading to better healthcare utilization and patient satisfaction.
Significant improvements in self-reported insomnia symptoms (SCI-8 score) for the dCBT group compared to control. Secondary outcomes included shorter sleep onset latencies and improved mood.
The study found that coronary artery disease and heart failure patients exhibited a higher prevalence and severity of SDB, particularly in older individuals. Low daytime oxygen saturation (SpO) and elevated body mass index (BMI) were significant indicators of SDB across all age categories and sexes, suggesting that effective management of these factors could lead to improved outcomes.
The TMR group experienced a significant reduction in the frequency of nightmares and reported more positive emotions in their dreams compared to the control group after two weeks of treatment. Additionally, the TMR group maintained a sustained decrease in nightmares over a three-month follow-up period.
CBT significantly reduced insomnia symptoms and improved sleep efficiency compared to TAU. At the end of the intervention, CBT participants reported greater improvements in fatigue and daytime sleep-related impairment.
Non-pharmacological interventions, particularly CBT-i, have shown to improve sleep quality and may enhance overall mental and physical health in psychiatric inpatients.
Improved treatment adherence and reduced Apnea Hypopnea Index (AHI) in compliant patients, leading to better overall sleep quality and daytime functioning.
The review found a significant association between sleep disturbance and cognitive impairment in mood disorders, suggesting that treating sleep issues may improve cognitive performance, particularly in individuals with BD.
Improved sleep could potentially reduce WMH accumulation and slow cognitive decline in older adults with AD and MCI.
Increased total sleep time, decreased sleep onset latency, and reduced waking after sleep onset in both mice and children with insomnia.
The study found that among Medicare beneficiaries with OSA, those who initiated PAP therapy had significantly lower all-cause mortality (hazard ratio 0.57) and lower incidence of major adverse cardiovascular events (MACE) (hazard ratio 0.90). Higher levels of PAP utilization were associated with progressively lower mortality and MACE incidence risks.
The study aims to assess improvements in sleep quality, quality of life, and reduction in PTSD-related symptoms among participants.
Participants in the LSD group experienced an increase in sleep duration by an average of 24.3 minutes the night after microdosing, with a 95% Confidence Interval of 10.3 to 38.3 minutes.
Participants experienced statistically significant improvements in subjective sleep quality, daytime alertness, insomnia symptoms, and anxiety levels, with trends suggesting that benefits may persist beyond the period of consumption.
Participants with high adherence to PAP therapy experienced significantly lower healthcare costs compared to those with moderate and low adherence, indicating that better adherence is associated with improved health outcomes and reduced financial burden.
Patients receiving CBTi showed decreased discrepancies in sleep latency and duration, improving overall sleep perception and quality.
The study found that a significant portion of the sample had potentially actionable sleep apnea, with 87.9% showing more than 5 events per hour. Treatment with CPAP can lead to improved sleep quality, better glycemic control, and reduced risk of complications associated with sleep apnea.
The study aims to provide evidence of improved outcomes measured by the BODE index, polysomnography results, cardiopulmonary exercise tests, Beck Depression Scale-II, and Saint George’s Respiratory Questionnaire, indicating enhanced respiratory function and quality of life.
Approximately two-thirds of patients with ASD experienced improved sleep after melatonin treatment, indicating its effectiveness in managing sleep disorders associated with ASD.
Both CBG and placebo groups showed trends towards improved sleep quality and quality of life, although no statistically significant differences were observed between the groups.
The study found that insomnia, poor sleep quality, and short sleep duration were associated with increased prevalence of PASC, suggesting that improving sleep may lower the risk of developing these sequelae.
Improvement in Glasgow Coma Scale (GCS) was noted in 5 out of 8 patients (62.5%). Modafinil prevented tracheostomy in 1 COVID-19 patient. The study suggests potential benefits in facilitating recovery from cognitive impairment in ICU patients.
The identification of Lateral PP as a novel phenotype provides insights into the diverse characteristics of OSA patients. The study found that Lateral PP patients were predominantly female, obese, and had mild to moderate OSA, suggesting that targeted interventions could improve outcomes for this specific group.
The workshop improved sleep knowledge and self-efficacy among students, with 83% applying learned skills in clinical practice after 12 months.
Significant improvement in total PSQI score from 9.42 ± 1.80 to 6.26 ± 1.66 (p<0.001). Sleep recovery scores improved significantly (p=0.042), and heart rate during sleep decreased by 1.3 bpm in the first week (p=0.045).
Elevated ANGPTL8 expression correlates with increased insulin levels, suggesting a potential target for therapeutic intervention in dyslipidemia associated with OSA.
More than 95% of participants reported improvement in at least one mental health outcome (anxiety, depression, or insomnia) after the intervention, with an average weight loss of 5.4% over approximately 88 days.
The study found that 68% of sleep apnea patients were smokers, indicating a strong association between smoking and the prevalence of OSA. The prevalence of OSA was higher among continuous smokers (16%), intermittent smokers (36%), and passive smokers (24%).
Patients with primary aldosteronism showed a significant association with severe obstructive sleep apnea, and elevated renin activity was negatively correlated with changes in AHI, suggesting potential improvement in sleep apnea symptoms with treatment.
The study found a significant increase in GHB prescriptions (88.5%) and spending (39.6%) among Medicaid patients from 2019 to 2021, indicating a growing acceptance and utilization of GHB for treating narcolepsy-related symptoms.
The study found that a significant proportion of patients (67.65%) received drug prescriptions, indicating a high level of pharmacological intervention for insomnia. The identification of commonly used drugs provides insights into treatment patterns and potential areas for improvement in prescribing practices.
The study indicates a significant increase in the prevalence of sleep disorders, with insomnia being the most common. The mean number of hospital visits per patient for sleep disorders was 11.5, suggesting a high engagement with healthcare services for management.
The intervention led to a significant reduction in the use of sleep-inducing drugs from 50.3% to 36.3% among patients, with a notable decrease in benzodiazepine prescriptions from 24.3% to 8.5%.
The study highlights the alarming prevalence of OSA in the ageing South African community and its association with increased cardiometabolic risk. It demonstrates the feasibility of using polysomnography (PSG) to detect OSA in rural settings, which can lead to improved health outcomes through early detection and treatment.